Identification of unmeasured confounder effects and
prevalence
We identified 4 studies reporting total exposure to MPA over dosing
interval at steady-state [AUC0-12 (mg ×h/L) calculated
based on dose-adjusted MPA concentrations] in renal transplant
patients classified in respect to the SCLO1B3
c.334T>G SNP as combined TT/TG subjects vs. GG subjects:
one French (Picard 2010 [1]) and one Dutch (Bouamar 2012 [2])
study, each reporting (separately) values in patients on IR MMF
co-treated with either CsA or macrolactams (mostly tacrolimus, less
commonly sirolimus); one Chinese study (Geng 2012 [3]) in which IR
MMF was combined with CsA; and one Japanese study (Miura 2007 [4])
in which IR MMF was combined with tacrolimus. All values were crude,
unadjusted mean±SD AUC0-12 quantified at different
post-transplantation times (Figure S2).